Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

SynAct Pharma

19.26 SEK0.00 %8/9 13:26
Less than 1K followers

SYNACT

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
0.00 %
+2.45 %
+42.88 %
+7.96 %
-14.78 %
+1.26 %
+0.39 %
-81.33 %
+317.82 %

SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.

Read more
Market cap
1.08B SEK
Turnover
1.7M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
3/11
2026

Interim report Q3'26

18/2
2027

Annual report '26

Press release2026-09-07 16:30

BioStock: SynAct on phase III plans following new ADVANCE data

SynAct Pharma
Third party research2026-09-07 15:12

Synact Pharma: Post-hoc analysis strengthens Phase III case - Edison

SynAct Pharma has reported further analysis of the Phase IIb ADVANCE study (testing resomelagon in rheumatoid arthritis), providing a clearer explanation for the unexpectedly strong placebo response. Management estimates that around 20% of patients entered...

SynAct Pharma
Press release2026-09-07 14:24

Investor Studios: SynAct Pharma: Interview with CBO Mads Bjerregaard & CSO Thomas Jonassen about the latest news

SynAct Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-09-07 11:00

Ytterligare analys av fas 2b-studien ADVANCE stärker resultaten från fas 2b-studien EXPAND och stödjer utveckling i fas 3 - diskussioner med FDA om studiedesign planeras till Q4 2026

SynAct Pharma
Press release2026-09-07 11:00

Further analysis of the Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and supports Phase 3 development - FDA discussions on trial design planned for Q4 2026

SynAct Pharma
Press release2026-09-03 07:30

SynAct Pharmas VD och CSO säljer aktier

SynAct Pharma
Press release2026-09-03 07:30

SynAct Pharma's CEO and CSO sell shares

SynAct Pharma
Press release2026-08-28 11:45

SynAct Pharma presenterar nya prekliniska data för bolagets fas 3-redo läkemedelskandidat inom reumatoid artrit resomelagon vid 17th World Congress of Inflammation 2026

SynAct Pharma
Press release2026-08-28 11:45

SynAct Pharma to present new resomelagon preclinical data on Phase 3-ready RA therapeutic candidate at the 17th World Congress of Inflammation 2026

SynAct Pharma
Third party research2026-08-27 09:29

Synact Pharma: Broader resomelagon opportunity taking shape - Edison

SynAct’s Q226 results marked a strategically important period in defining resomelagon’s clinical and commercial opportunity. Following June’s Phase IIb ADVANCE data, we expect RA to remain the principal value driver, with ACR20, CRP and SDAI signals ...

SynAct Pharma
Press release2026-08-20 15:32

Redeye: SynAct Pharma (Q2 Review): Fenja Financing Backs the Post-ADVANCE Push

SynAct Pharma
Third party research2026-08-20 10:19

Synact Pharma: Q226 results highlight resomelagon progress - Edison

SynAct Pharma reported Q226 operating expenses of SEK24.6m, down 19% y-o-y, while the net loss narrowed to SEK22.0m and quarter-end cash stood at SEK14.2m. Post-period, the company secured a new financing facility of up to SEK100m from Fenja Capital,...

SynAct Pharma
Regulatory press release2026-08-20 07:30

SynAct Pharma publicerar delårsrapport Q2 2026

SynAct Pharma
Regulatory press release2026-08-20 07:30

SynAct Pharma publishes Q2 2026 interim results

SynAct Pharma
Press release2026-08-19 12:56

Redeye: SynAct Pharma: Term Sheet Signed for Brazil

SynAct Pharma
Third party research2026-08-19 09:27

Synact Pharma: Brazil partnership advances dengue opportunity - Edison

SynAct Pharma has signed a term sheet with established Brazilian pharmaceutical company Hipolabor for the co-development and commercialisation of resomelagon for dengue and other viral infections in Brazil. We view this agreement positively, as it builds...

SynAct Pharma
Regulatory press release2026-08-19 07:00

SynAct Pharma tar nästa steg mot det första kommersiella avtalet för resomelagon vid behandling av denguefeber i Brasilien – term sheet undertecknat

SynAct Pharma
Regulatory press release2026-08-19 07:00

SynAct Pharma progresses first commercial agreement on resomelagon for treatment of dengue in Brazil – term sheet signed

SynAct Pharma
Press release2026-08-05 15:26

SynAct Pharma erhåller positivt patentbeslut i USA avseende tablettformulering med omedelbar frisättning av resomelagon

SynAct Pharma
Press release2026-08-05 15:26

SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation

SynAct Pharma